Activin RIIB

Activin RIIB 분자 정보

영어 이름Activin receptor type-2B시판 약물 수0
임상 약물 수6표적 별명EC:2.7.11.30,EC 2.7.11,Activin receptor type IIB,ACVR2B,Activin A Receptor Type 2B,Activin A Receptor, Type IIB,Activin Receptor Type-2B,EC 2.7.11.30,ActR-IIB,ACTRIIB,HTX4
최고 연구 개발 단계Phase 2 Clinical
영어 이름Activin receptor type-2B
표적 별명EC:2.7.11.30,EC 2.7.11,Activin receptor type IIB,ACVR2B,Activin A Receptor Type 2B,Activin A Receptor, Type IIB,Activin Receptor Type-2B,EC 2.7.11.30,ActR-IIB,ACTRIIB,HTX4
시판 약물 수0
임상 약물 수6
최고 연구 개발 단계Phase 2 Clinical

Activin RIIB 제품 목록

  • 속성

    Protein (7)

  • 제품 라이브러리

    온라인 (7)

  • Human (4)Mouse (2)Rabbit (1)

  • 태그

    His Tag (3)His Tag & Avi Tag (2)Fc Tag (1)Fc Tag & Avi Tag (1)

  • 마커

    Unconjugated (4)Biotin-labeled (3)

Activin RIIB분자 배경

Activin receptor type-2B (ACVR2B) is also known as ActR-IIB and MGC116908, ACVR2B is an activin type 2 receptor. Activins are dimeric growth and differentiation factors which belong to the transforming growth factor-beta (TGF-beta) superfamily of structurally related signaling proteins. Activins signal through a heteromeric complex of receptor serine kinases which include at least two type I (I and IB) and two type II (II and IIB) receptors. These receptors are all transmembrane proteins, composed of a ligand-binding extracellular domain with cysteine-rich region, a transmembrane domain, and a cytoplasmic domain with predicted serine/threonine specificity. Type I receptors are essential for signaling; and type II receptors are required for binding ligands and for expression of type I receptors. Type I and II receptors form a stable complex after ligand binding, resulting in phosphorylation of type I receptors by type II receptors. Type II receptors are considered to be constitutively active kinases. This gene encodes activin A type IIB receptor, which displays a 3- to 4-fold higher affinity for the ligand than activin A type II receptor. Defects in ACVR2B are the cause of visceral heterotaxy autosomal type 4 (HTX4).

Activin RIIB분자 별명

ACVR2B,ACTRIIB,MGC116908

임상 약물 정보

영어 이름연구 코드연구 개발 단계회사적응증임상 시험
BimagrumabLY-3985863; BYM-338Phase 2 ClinicalMorphosys Ag, Novartis Pharma AgDiabetes Mellitus, Type 2; Myositis, Inclusion Body; Obesity; Overweight; Pulmonary Disease, Chronic Obstructive; Sarcopenia
상세
BIIB-110BIIB-110; BIIB110; ALG-801Phase 1 ClinicalAlivegen USA IncMuscular Atrophy, Spinal; Muscular Diseases
상세
LAE-103LAE-103; LAE103Phase 1 ClinicalLaekna Therapeutics Shanghai Co LtdMuscular Diseases; Muscular Disorders, Atrophic; Obesity; Sarcopenia
상세
SSS-67SSS67; SSS-67Phase 1 ClinicalShenyang Sunshine Pharmaceutical Co LtdObesity; Overweight
상세
JMT-206JMT206; JMT-206Phase 1 ClinicalShanghai Jmt-Bio IncBody Weight; Obesity; Overweight; Sarcopenia
상세
Tirzepatide/BimagrumabLY-900042Phase 1 ClinicalEli Lilly And Company
상세
  • 분자 정보
  • 제품 목록
  • 임상 약물 정보
문의하기

전화
글로벌: +1 800-810-0816 (무료)
아시아태평양: +86 400-682-2521

주소 서울특별시 송파구 법원로11길 11, 제3층 제비-314,315호